Interventional Recruiting Phase 2 Enrollment (Estimated) Enrollment 23 (Estimated)
View on ClinicalTrials.gov NCT04837885 Other Study ID: CHUBX 2017/47
Intra-arterial Hepatic (IAH) Infusion of Radiolabelled Somatostatin Analogs in GEP-NET Patients With Dominant Liver Metastases "Imaging With 68Ga-DOTA-peptides and Peptide Receptor Radionuclide Therapy With 177Lu-DOTA-peptides of Gastroenteropancreatic Neuroendocrine Tumors: Interest of Intra-arterial Hepatic Infusion in Patients With Dominant Liver Metastases"
First Submitted: April 6, 2021
Last Update Posted: July 23, 2025
Study duration (Estimated)
5 years 6 months 2 daysStudy Start
2021-09-24
Actual
Primary Completion
2025-09-24
Estimated
Study Completion
2027-03-24
Estimated
Study duration
5 years 6 months 2 days (Estimated)
Brief Summary
The management of liver metastases in neuroendocrine neoplasms is challenging. Peptide receptor radionuclide therapy with radiolabeled somatostatin analogs (SSA) is one of the most promising therapeutic options. As liver is the most frequent site of metastatic disease, our project proposes to compare administration of radiolabeled SSA by arterial intrahepatic infusion (experimental approach) vs intravenous administration (conventional). Evaluation will be made by (i) comparing 68Ga-DOTA-peptides uptake after intra-hepatic versus intravenous route (imaging), (ii) by evaluating the safety of an additional intra-hepatic administration of therapeutic radiolabeled SSA (therapy).
Conditions
- Neuroendocrine Tumor
- •
- Liver Metastases
- •
- Neuroendocrine Gastroenteropancreatic Tumour
Intervention / Treatment
- Procedure Positron emission tomography computed tomography (PET/CT) with Intra-hepatic (IAH) injection
- Procedure Positron emission tomography computed tomography (PET/CT) with Intravenous (IV) injection
- Drug LUTATHERA® by intra-arterial hepatic (IAH) injection
- Procedure Scan
Contacts and Locations
Nimes Cedex 9
France, 30029
Centre Hospitalier Universitaire De Nimes
Bordeaux
France, 33000
Institut Bergonie
Toulouse
France, 31100
Oncopole Claudius Regaud
Montpellier Cedex 5
France, 34298
Institut Regional Du Cancer De Montpellier
Pessac
France, 33600
Centre Hospitalier Universitaire De Bordeaux
Participation Criteria
|
Sexes Eligible
|
Accepts Healthy Volunteers
|
Ages Eligible
|
|---|---|---|
| ALL | No | 18 Years and older |
Inclusion Criteria
• Patients are progressive after treatment with cold somatostatin analog (within 12 months according to RECIST), or as soon as the diagnosis is made in case of hepatic invasion > 50% without waiting for tumour progression
• Patient has received 4 standard of care LUTATHERA® cycles
• Liver Metastatic disease dominant or exclusive and assessable by RECIST 1.1, and not amenable to surgical resection after the last cycle
• ECOG performance status 0-2
• Adequate kidney and liver function: creatinine clearance ≥ 50 mL/min, ALT/AST ≤ 2,5x the upper limit of normal
• With no evidence of hematologic alteration after 4 LUTATHERA® cycles: hemoglobin ≥ 8 g/dL, neutrophils ≥ 1500/ mm3, platelets ≥ 75.000/mm3
• Age ≥ 18 years, no superior limit
• Contraception required in pre-menopausal female (Intrauterine device, Progestin Pills, Combined Oral Contraceptives, Monthly Injectables, Progestin Injectables, Combined Patch, Combined Vaginal Ring, Female Sterilization, Vasectomy, Implants) and men for at least 6 months after the last LUTATHERA ® injection.
• Patient´s signed written informed consent
• Patient affiliated to a social security system
Exclusion Criteria
• No residual uptake according to standard 177-Lu scintigraphy performed in the clinical routine 24 hours after each LUTATHERA IV treatment
• Carcinoid heart disease (LVEF < 40%)
• Dominant or threatening extrahepatic metastases or that may affect vital prognosis
• Contraindications to intra-hepatic arterial infusion (coagulation disorders, portal thrombosis, intra-hepatic biliary tract dilatation, digestive or biliary anastomosis or fistula, cirrhosis (Child Pugh B8 or C...)
• Serum albumin <30 g/L unless prothrombin time is within the normal range.
• Heart failure, myocardial infarction, stroke, uncontrolled arterial hypertension under optimal treatment (≥ 160/95 mmHg), pulmonary embolism or revascularization procedure, unstable angina pectoris, uncontrolled cardiac arrhythmia, and clinically significant bradycardia during the last 12 months.
• Individuals under legal protection or unable of giving their informed consent
• Pregnancy or breast feeding
• Currently participating to another clinical research protocol
• Individuals under legal protection or unable of giving their informed consent
• MRI scan contraindicated
• LUTATHERA® contraindicated or toxicity during one of the IV administrations leading to a reduction or cancellation of the following dose
Participant Groups/Arms
Diseases
- Digestive System Diseases
Collaborators and Investigators
Keywords
- Neuroendocrine tumour
- •
- Neuroendocrine gastroenteropancreatic (GEP) tumour
- •
- Liver Metastases
- •
- 68Ga- DOTA-peptides PET CT
- •
- 177Lutetium-Octreotate
- •
- Peptide Receptor Radionuclide Therapy
References
Outcome Measures
|
Outcome Measure
|
Measure Description
|
Time Frame
|
|---|---|---|
| Standardized uptake value (SUVmax) on liver metastases | Standardized uptake value (SUVmax) on liver metastase obtained on PET/CT imaging after injection of 68Ga-DOTA-peptides | Day 0 (First PET/CT) |
| Standardized uptake value (SUVmax) on liver metastases | Standardized uptake value (SUVmax) on liver metastase obtained on PET/CT imaging after injection of 68Ga-DOTA-peptides | Day 3 (second PET/CT) |
|
Outcome Measure
|
Measure Description
|
Time Frame
|
|---|---|---|
|
|
|
|
| Standardized uptake value (SUVmax) on healthy liver | Standardized uptake value (SUVmax) on healthy liver obtained on PET/CT imaging after injection of 68Ga-DOTA-peptides | Day 0 (First PET/CT) |
| Standardized uptake value (SUVmax) on healthy liver | Standardized uptake value (SUVmax) on healthy liver obtained on PET/CT imaging after injection of 68Ga-DOTA-peptides | Day 3 (second PET/CT) |
| Standardized uptake value (SUVmax) on kidneys | Standardized uptake value (SUVmax) on kidneys obtained on PET/CT imaging after injection of 68Ga-DOTA-peptides | Day 0 (First PET/CT) |
| Standardized uptake value (SUVmax) on kidneys | Standardized uptake value (SUVmax) on kidneys obtained on PET/CT imaging after injection of 68Ga-DOTA-peptides | Day 3 (second PET/CT) |
| Standardized uptake value (SUVmax) on bone marrow | Standardized uptake value (SUVmax) on bone marrow obtained on PET/CT imaging after injection of 68Ga-DOTA-peptides | Day 0 (First PET/CT) |
| Standardized uptake value (SUVmax) on bone marrow | Standardized uptake value (SUVmax) on bone marrow obtained on PET/CT imaging after injection of 68Ga-DOTA-peptides | Day 3 (second PET/CT) |
| Standardized uptake value (SUVmax) on spleen | Standardized uptake value (SUVmax) on spleen obtained on PET/CT imaging after injection of 68Ga-DOTA-peptides | Day 0 (First PET/CT) |
| Standardized uptake value (SUVmax) on spleen | Standardized uptake value (SUVmax) on spleen obtained on PET/CT imaging after injection of 68Ga-DOTA-peptides | Day 3 (second PET/CT) |
| Standardized uptake value (SUVmax) on associated extra-hepatic metastases | Standardized uptake value (SUVmax) on associated extra-hepatic metastases obtained on PET/CT imaging after injection of 68Ga-DOTA-peptides | Day 0 (First PET/CT) |
| Standardized uptake value (SUVmax) on associated extra-hepatic metastases | Standardized uptake value (SUVmax) on associated extra-hepatic metastases obtained on PET/CT imaging after injection of 68Ga-DOTA-peptides | Day 3 (second PET/CT) |
| 177Lu-DOTA-peptide dosimetry | Absorbed dose in different tissue of the 5 hepatic targets, possible extra-hepatic lesions and healthy organs (healthy liver, kidney, bone marrow, spleen) | Day 18 |